Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.87 Million USD | -46.73% |
| 2022 | -14.22 Million USD | 9.11% |
| 2021 | -15.65 Million USD | 40.93% |
| 2020 | -26.36 Million USD | -71.02% |
| 2019 | -15.49 Million USD | -56.87% |
| 2018 | -9.87 Million USD | -48.72% |
| 2017 | -6.44 Million USD | 21.18% |
| 2016 | -8.41 Million USD | 27.1% |
| 2015 | -11.65 Million USD | -100.97% |
| 2014 | -5.75 Million USD | 64.3% |
| 2013 | -15.97 Million USD | -30.53% |
| 2012 | -12.35 Million USD | -69.86% |
| 2011 | -7.26 Million USD | 7.52% |
| 2010 | -8.46 Million USD | -28.99% |
| 2009 | -5.23 Million USD | -5.69% |
| 2008 | -5.75 Million USD | -179.2% |
| 2007 | -2.03 Million USD | 23.07% |
| 2006 | -2.65 Million USD | 10.67% |
| 2005 | -2.96 Million USD | 2.57% |
| 2004 | -3.08 Million USD | -86.22% |
| 2003 | -1.65 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.3 Million USD | 5.92% |
| 2024 Q1 | -2.46 Million USD | 81.13% |
| 2023 Q3 | -1.99 Million USD | 34.38% |
| 2023 Q1 | -2.83 Million USD | -897.34% |
| 2023 Q2 | -3.03 Million USD | -7.36% |
| 2023 Q4 | -2.52 Million USD | -26.53% |
| 2023 FY | - USD | 25.21% |
| 2022 FY | - USD | 9.11% |
| 2022 Q3 | -3.89 Million USD | 3.03% |
| 2022 Q4 | -283.77 Thousand USD | 92.72% |
| 2022 Q1 | -6.02 Million USD | -164.07% |
| 2022 Q2 | -4.02 Million USD | 33.24% |
| 2021 Q3 | -4.36 Million USD | -14.87% |
| 2021 Q4 | -2.28 Million USD | 47.77% |
| 2021 Q1 | -5.2 Million USD | -18.5% |
| 2021 Q2 | -3.8 Million USD | 26.95% |
| 2021 FY | - USD | 40.93% |
| 2020 FY | - USD | -71.02% |
| 2020 Q2 | -12.32 Million USD | -138.23% |
| 2020 Q1 | -5.17 Million USD | -44.65% |
| 2020 Q4 | -4.39 Million USD | 1.96% |
| 2020 Q3 | -4.47 Million USD | 63.65% |
| 2019 Q4 | -3.57 Million USD | 6.28% |
| 2019 FY | - USD | -56.87% |
| 2019 Q3 | -3.81 Million USD | 20.38% |
| 2019 Q1 | -3.31 Million USD | -20.78% |
| 2019 Q2 | -4.79 Million USD | -44.72% |
| 2018 FY | - USD | -48.72% |
| 2018 Q2 | -2.27 Million USD | -7.89% |
| 2018 Q4 | -2.74 Million USD | 0.24% |
| 2018 Q3 | -2.74 Million USD | -20.68% |
| 2018 Q1 | -2.11 Million USD | -51.16% |
| 2017 Q2 | -1.37 Million USD | 30.01% |
| 2017 Q1 | -1.96 Million USD | 26.32% |
| 2017 Q4 | -1.39 Million USD | 26.54% |
| 2017 Q3 | -1.9 Million USD | -38.02% |
| 2017 FY | - USD | 21.18% |
| 2016 Q4 | -2.67 Million USD | -34.26% |
| 2016 FY | - USD | 27.1% |
| 2016 Q3 | -1.98 Million USD | -16.08% |
| 2016 Q2 | -1.71 Million USD | 16.11% |
| 2016 Q1 | -2.04 Million USD | 6.02% |
| 2015 Q3 | -1.8 Million USD | 71.39% |
| 2015 FY | - USD | -100.97% |
| 2015 Q4 | -2.17 Million USD | -20.45% |
| 2015 Q2 | -6.3 Million USD | -394.28% |
| 2015 Q1 | -1.27 Million USD | -5.02% |
| 2014 Q3 | -1.01 Million USD | 45.95% |
| 2014 FY | - USD | 64.3% |
| 2014 Q1 | -1.63 Million USD | 46.55% |
| 2014 Q2 | -1.88 Million USD | -15.59% |
| 2014 Q4 | -1.21 Million USD | -19.17% |
| 2013 FY | - USD | -30.53% |
| 2013 Q3 | -9.29 Million USD | -353.86% |
| 2013 Q1 | -1.7 Million USD | 12.85% |
| 2013 Q4 | -3.05 Million USD | 67.18% |
| 2013 Q2 | -2.04 Million USD | -19.92% |
| 2012 Q4 | -1.96 Million USD | 5.38% |
| 2012 Q1 | -1.45 Million USD | 18.78% |
| 2012 FY | - USD | -69.86% |
| 2012 Q2 | -6.84 Million USD | -369.52% |
| 2012 Q3 | -2.07 Million USD | 69.75% |
| 2011 Q1 | -1.49 Million USD | 33.73% |
| 2011 Q4 | -1.79 Million USD | -6.21% |
| 2011 Q2 | -2.28 Million USD | -52.76% |
| 2011 FY | - USD | 7.52% |
| 2011 Q3 | -1.69 Million USD | 25.95% |
| 2010 Q2 | -2 Million USD | -15.99% |
| 2010 FY | - USD | -28.99% |
| 2010 Q4 | -2.25 Million USD | -20.88% |
| 2010 Q1 | -1.72 Million USD | -36.73% |
| 2010 Q3 | -1.86 Million USD | 6.86% |
| 2009 Q4 | -1.26 Million USD | 9.83% |
| 2009 FY | - USD | -5.69% |
| 2009 Q1 | -1.91 Million USD | 33.43% |
| 2009 Q2 | -1.51 Million USD | 21.06% |
| 2009 Q3 | -1.4 Million USD | 7.27% |
| 2008 Q3 | -1.08 Million USD | -3.12% |
| 2008 Q1 | -743.3 Thousand USD | -18.97% |
| 2008 FY | - USD | -179.2% |
| 2008 Q4 | -2.87 Million USD | -164.27% |
| 2008 Q2 | -1.05 Million USD | -41.98% |
| 2007 Q2 | -527.5 Thousand USD | -9.49% |
| 2007 Q1 | -481.77 Thousand USD | 26.66% |
| 2007 Q4 | -624.8 Thousand USD | -46.25% |
| 2007 Q3 | -427.2 Thousand USD | 19.01% |
| 2007 FY | - USD | 23.07% |
| 2006 Q2 | -731.21 Thousand USD | 8.18% |
| 2006 Q4 | -656.89 Thousand USD | -31.79% |
| 2006 Q3 | -498.44 Thousand USD | 31.83% |
| 2006 FY | - USD | 10.67% |
| 2006 Q1 | -796.39 Thousand USD | -15.86% |
| 2005 Q3 | -679.3 Thousand USD | 15.77% |
| 2005 Q1 | 927.9 Thousand USD | 174.28% |
| 2005 FY | - USD | 2.57% |
| 2005 Q2 | -806.44 Thousand USD | -186.91% |
| 2005 Q4 | -687.38 Thousand USD | -1.19% |
| 2004 Q2 | -673.75 Thousand USD | -222.58% |
| 2004 Q1 | 549.62 Thousand USD | 187.91% |
| 2004 Q3 | -620.56 Thousand USD | 7.89% |
| 2004 Q4 | -1.24 Million USD | -101.29% |
| 2004 FY | - USD | -86.22% |
| 2003 Q2 | -429.83 Thousand USD | -109.24% |
| 2003 Q4 | -625.24 Thousand USD | -58.33% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | -394.89 Thousand USD | 8.13% |
| 2003 Q1 | -205.43 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 34.095% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 47.699% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 59.168% |
| Azitra, Inc. | -10.67 Million USD | -95.607% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -155.226% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -204.236% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 27.002% |
| CEL-SCI Corporation | -27.56 Million USD | 24.249% |
| iBio, Inc. | -14.02 Million USD | -48.902% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 15.588% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -3.444% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 8.532% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -50.467% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -334.948% |
| NanoViricides, Inc. | -7.75 Million USD | -169.141% |
| BiomX Inc. | -22.81 Million USD | 8.492% |
| BiomX Inc. | -22.81 Million USD | 8.492% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 279.191% |
| Palatin Technologies, Inc. | -29.03 Million USD | 28.086% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 40.49% |